Vectibix (panitumumab) - Amgen
Tukysa (tucatinib) - Pfizer
Krazati (adagrasib) - BMS
Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca
Erbitux (cetuximab) - Eli Lilly
5-fluorouracil - Generic mfg.
Braftovi (encorafenib) - Pfizer
irinotecan - Generic mfg.
Avastin (bevacizumab) - Roche
leucovorin calcium - Generic mfg.
Lumakras (sotorasib) - Amgen
Lonsurf (trifluridine/tipiracil) - Otsuka
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 15, 2026 - P1 | N=100 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting 
Enrollment open • Colorectal Cancer • Oncology • Solid Tumor • MSI
http://clinicaltrials.gov/ct2/show/NCT07318389
 
Oct 15, 2026
 
Prev Next